3 completed, 3 terminated, 1 active not recruiting. 5 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 3, Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Symptomatic Neurogenic Orthostatic Hypotension: new trials by email Literature Review of Symptomatic Neurogenic Orthostatic Hypotension trials Research Report on Symptomatic Neurogenic Orthostatic Hypotension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy Ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | Active not recruiting | Theravance Biopharma | 102 | 2023-06-27 | 2025-09-05 |
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Terminated | Theravance Biopharma | 110 | 2019-09-19 | 2022-11-30 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA | Phase 3 | Terminated | Theravance Biopharma | 203 | 2019-02-22 | 2023-01-20 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Droxidopa capsules, Placebo capsules - Symptomatic Neurogenic Orthostatic Hypotension | Phase 4 | Completed | H. Lundbeck A/S | 453 | 2016-02-11 | 2023-08-23 |
| A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Droxidopa, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease | Phase 3 | Terminated | Chelsea Therapeutics | 61 | 2013-11-01 | 2016-01-08 |
| Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension | Phase 1 | Completed | Chelsea Therapeutics | 24 | 2010-07-01 | 2013-03-20 |
Parkinson Disease (5) · Pure Autonomic Failure (5) · Dizziness (3) · Hypotension (3) · Syncope (3) · Hypotension, Orthostatic (2) · Multiple System Atrophy (2) · Parkinsonian Disorders (2) · dopamine beta hydroxylase deficiency (2) · Shy-Drager Syndrome (1)
Autonomic Nervous System Diseases (6) · Basal Ganglia Diseases (6) · Brain Diseases (6) · Central Nervous System Diseases (6) · Movement Disorders (6) · Nervous System Diseases (6) · Primary Dysautonomias (6) · Neurodegenerative Diseases (5) · Synucleinopathies (5) · Cardiovascular Diseases (4) · Vascular Diseases (4) · Consciousness Disorders (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Parkinsonian Disorders (3)
ampreloxetine (4) · Droxidopa (3) · Mannitol (1)
Theravance Biopharma (4) · Chelsea Therapeutics (2) · H. Lundbeck A/S (1)
United States (7) · Australia (4) · Austria (4) · Canada (4) · Denmark (4) · Estonia (4) · France (4) · Germany (4) · Israel (4) · Italy (4) · New Zealand (4) · Poland (4) · Portugal (4) · Spain (4) · United Kingdom (4)
Gregory M Haugen, M.D. (1) · Horacio Kaufmann, M.D. (1)
PMID 42475649, PMID 29392574, PMID 35107750
2018 (2), 2019 (1)